Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

eV3 targets US PAD (peripheral artery disease) market:

This article was originally published in Clinica

Executive Summary

Eyeing a wider market opportunity for its Protege EverFlex self-expanding stent, ev3 is to begin a US clinical trial to test the device as a treatment for peripheral artery disease (PAD). The product is already available in the US for the palliative treatment of malignant neoplasms in the biliary tree. The US trial, called DURABILITY II, will be the first study in the treatment of PAD to explore use of a single stent in the treatment of lesions as long as 16cm and will include rigorous, five-year follow-up on stent fracture, claimed the Plymouth, Minnesota firm. According to the American Heart Association, PAD affects 8 million people in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel